September 13 Edition
September 12 Edition
September 11 Edition

ACTRIMS/ECTRIMS 2020 concluded on September 26^th with a special session on COVID-19. Presentations and posters attempted to clarify risk factors for COVID-19 in MS patients, and to address the question of whether disease-modifying therapies (DMT) – most specifically anti-CD20 therapies – affect the risk of acquiring SARS-CoV-2 infection or clinical outcomes of COVID-19. Data were provided by large multinational patient registries and individual MS centres.

Read More

8th Joint Americas Committee and European Committee for Treatment and Research in MS (ACTRIMS-ECTRIMS) meeting, Virtual Congress, 11-13 September 2020.

The following summarizes some of the highlights from Day 3 of ACTRIMS-ECTRIMS 2020.

September 26 Edition (special session on COVID-19)
September 12 Edition
September 11 Edition

Read More

8th Joint Americas Committee and European Committee for Treatment and Research in MS (ACTRIMS-ECTRIMS) meeting, Virtual Congress, 11-13 September 2020.

The following summarizes some of the highlights from Day 2 of ACTRIMS-ECTRIMS 2020.

September 26 Edition (special session on COVID-19)
September 13 Edition
September 11 Edition

Read More